<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        73-5286-20
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2020
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        GEBTIN
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        GEMCITABINE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        200
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intravenous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Powder for injection
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Vial
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        42.25
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Jiangsu Hansoh Pharmaceutical Group Co" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Jiangsu Hansoh Pharmaceutical Group Co
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 359]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Cigalah Group
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            MS Pharma Saudi (MSPS)
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        L01BC05 
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&nbsp;</p><p>Gebtin<sup>&reg;</sup> belongs to a group of medicines called &ldquo;cytotoxics&rdquo;. These medicines kill dividing cells, including cancer cells.</p><p>&nbsp;</p><p>Gebtin<sup>&reg;</sup> may be given alone or in combination with other anti-cancer medicines, depending on the type of cancer.</p><p>&nbsp;</p><p>Gebtin<sup>&reg;</sup> is used in the treatment of the following types of cancer:</p><p>&bull;non-small cell lung cancer (NSCLC), alone or together with cisplatin</p><p>&bull;pancreatic cancer.</p><p>&bull;breast cancer, together with paclitaxel.</p><p>&bull;ovarian cancer, together with carboplatin.</p><p>&bull;bladder cancer, together with cisplatin.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>You should not be given Gebtin<sup>&reg;</sup>:</p><p>-if you are allergic (hypersensitive) to gemcitabine or any of the other ingredients of Gebtin<sup>&reg;</sup>.</p><p>-if you are breast-feeding</p><p>&nbsp;</p><p><strong>Take special care with </strong>Gebtin<sup>&reg;</sup><strong>: </strong>Before the first infusion you will have samples of your blood taken to evaluate if you have sufficient kidney and liver function. Before each infusion you will have samples of your blood taken to evaluate if you have enough blood cells to receive Gebtin<sup>&reg;</sup>. Your doctor may decide to change the dose or delay treating you depending on your general condition and if your blood cell counts are too low. Periodically you will have samples of your blood taken to evaluate your kidney and liver function.</p><p>&nbsp;</p><p>Please tell your doctor if: you have, or have previously had liver disease, heart disease or vascular disease.</p><p>&nbsp;</p><p>&bull;you have recently had, or are going to have radiotherapy,</p><p>&bull;you have been vaccinated recently</p><p>&bull;you develop breathing difficulties or feel very weak and are very pale (may be a sign of kidney failure).</p><p>Men are advised not to father a child during and up to 6 months following treatment with Gebtin<sup>&reg;</sup>. If you would like to father a child during the treatment or in the 6 months following treatment, seek advice from your doctor or pharmacist. You may want to seek counseling on sperm storage before starting your therapy.</p><p>&nbsp;</p><p><strong>Taking other medicines</strong></p><p>Please tell your doctor or hospital pharmacist if you are taking or have recently taken any other medicines, including vaccinations and medicines obtained without a prescription.</p><p>&nbsp;</p><p><strong>Pregnancy and breast-feeding</strong></p><p>If you are pregnant, or thinking about becoming pregnant, tell your doctor. The use of Gebtin<sup>&reg;</sup> should be avoided during pregnancy. Your doctor will discuss with you the potential risk of taking Gebtin<sup>&reg;</sup> during pregnancy.</p><p>&nbsp;</p><p>If you are breast-feeding, tell your doctor. You must discontinue breast-feeding during Gebtin<sup>&reg;</sup> treatment.</p><p>&nbsp;</p><p><strong>Driving and using machines</strong></p><p>Gebtin<sup>&reg;</sup> may make you feel sleepy, particularly if you have consumed any alcohol. Do not drive a car or use machinery until you are sure that Gebtin<sup>&reg;</sup> treatment has not made you feel sleepy.</p><p>&nbsp;</p><p><strong>Important information about some of the ingredients of </strong>Gebtin<sup>&reg;</sup><strong> </strong>Gebtin<sup>&reg;</sup> contains 3.5 mg (&lt; 1 mmol) of sodium in each 200 mg vial and 17.5 mg (&lt; 1 mmol) sodium in each 1000 mg vial. To be taken into consideration by patients on a controlled sodium diet.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>&nbsp;</strong></p><p>The usual dose of Gebtin<sup>&reg;</sup> is 1000-1250 mg for every square metre of your body&rsquo;s surface area. Your height and weight are measured to work out the surface area of your body. Your doctor will use this body surface area to work out the right dose for you. This dosage may be adjusted, or treatment may be delayed depending on your blood cell counts and on your general condition.</p><p>&nbsp;</p><p>How frequently you receive your Gebtin<sup>&reg;</sup> infusion depends on the type of cancer that you are being treated for.</p><p>A hospital pharmacist or doctor will have dissolved the Gebtin<sup>&reg;</sup> powder before it is given to you.</p><p>You will always receive Gebtin<sup>&reg;</sup> by infusion into one of your veins. The infusion will last approximately 30 minutes.</p><p>If you have further questions on the use of this product ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>&nbsp;</strong></p><p>Like all medicines, Gebtin<sup>&reg;</sup> can cause side effects, although not everybody gets them.</p><p>&nbsp;</p><p>Frequencies of the observed side effects are defined as:</p><p>&bull;very common: affects more than 1 user in 10</p><p>&bull;common: affects 1 to 10 users in 100</p><p>&bull;uncommon: affects 1 to 10 users in 1,000</p><p>&bull;rare: affects 1 to 10 users in 10,000</p><p>&bull;very rare: affects less than 1 user in 10,000</p><p>&bull;not known: frequency can&rsquo;t be estimated from the available data</p><p>&nbsp;</p><p><strong>You must contact your doctor immediately if you notice any of the following:</strong></p><p>&bull;Fever or infection (common): if you have a temperature of 38&ordm;C or greater, sweating or other signs of infection (since you might have less white blood cells than normal which is very common).</p><p>&bull;Irregular heart rate (arrhythmia) (frequency not known).</p><p>&bull;Pain, redness, swelling or sores in your mouth (common).</p><p>&bull;Allergic reactions: if you develop skin rash (very common) / itching (common), or fever (very common).</p><p>&bull;Tiredness, feeling faint, becoming easily breathless or if you look pale (since you might have less haemoglobin than normal which is very common).</p><p>&bull;Bleeding from the gums, nose or mouth or any bleeding that would not stop, reddish or pinkish urine, unexpected bruising (since you might have less platelets than normal which is very common).</p><p>&bull;Difficulty breathing (it is very common to have mild breathing difficulty soon after the Gebtin<sup>&reg;</sup> infusion which soon passes, however uncommonly or rarely there can be more severe lung problems)</p><p>&nbsp;</p><p><strong>Side effects with </strong>Gebtin<sup>&reg;</sup><strong> may include: Very common side effects</strong></p><p>&bull;Low haemoglobin level (anaemia)</p><p>&bull;Low white blood cells</p><p>&bull;Low platelet count</p><p>&bull;Difficulty breathing</p><p>&bull;Vomiting</p><p>&bull;Nausea</p><p>&bull;Skin rash- allergic skin rash, frequently itchy</p><p>&bull;Hair loss</p><p>&bull;Liver problems: found through abnormal blood test results</p><p>&bull;Blood in urine</p><p>&bull;Abnormal urine tests: protein in urine</p><p>&bull;Flu like symptoms including fever</p><p>&bull;Oedema (swelling of ankles, fingers, feet, face)</p><p>&nbsp;</p><p>C<strong>ommon side effects</strong></p><p>&bull;Fever accompanied by low white blood cell count (febrile neutropaenia)</p><p>&bull;Anorexia (poor appetite)</p><p>&bull;Headache</p><p>&bull;Insomnia</p><p>&bull;Sleepiness</p><p>&bull;Cough</p><p>&bull;Runny nose</p><p>&bull;Constipation</p><p>&bull;Diarrhoea</p><p>&bull;Pain, redness, swelling or sores in the mouth</p><p>&bull;Itching</p><p>&bull;Sweating</p><p>&bull;Muscle pain</p><p>&bull;Back pain</p><p>&bull;Fever</p><p>&bull;Weakness</p><p>&bull;Chills</p><p><strong>Uncommon side effects</strong></p><p>&bull;Interstitial pneumonitis (scarring of the air sacs of the lung) Spasm of the airways (wheeze)</p><p>&bull;Abnormal chest X-ray/scan (scarring of the lungs)</p><p>Rare side effects</p><p>&bull;Heart attack (myocardial infarction)</p><p>&bull;Low blood pressure</p><p>&bull;Skin scaling, ulceration or blister formation</p><p>&bull;Injection site reactions</p><p>Very rare side effects</p><p>&bull;Increased platelet count</p><p>&bull;Anaphylactic reaction (severe hypersensitivity/ allergic reaction)</p><p>&bull;Sloughing of skin and severe skin blistering</p><p><strong>Side effects with frequency not known</strong></p><p>&bull;Irregular heart beat (arrhythmia)</p><p>&bull;Adult Respiratory Distress Syndrome (severe lung inflammation causing respiratory failure)</p><p>&bull;Radiation recall-(a skin rash like severe sunburn) which can occur on skin that has previously been exposed to radiotherapy.</p><p>&bull;Fluid in the lungs</p><p>&bull;Radiation toxicity- scarring of the air sacs of the lung associated with radiation therapy</p><p>&bull;Ischaemic colitis (inflammation of the lining of the large bowel, caused by reduced blood supply)</p><p>&bull;Heart failure</p><p>&bull;Kidney failure</p><p>&bull;Gangrene of fingers or toes</p><p>&bull;Serious liver damage, including liver failure</p><p>&bull;Stroke</p><p>&nbsp;</p><p>You might have any of these symptoms and/or conditions. You must tell your doctor as soon as possible when you start experiencing any of these side effects.</p><p>If you are concerned about any side effects, talk to your doctor.</p><p>If any of the side effects gets serious, or if you notice any side effects not mentioned in this leaflet, please tell your doctor.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&bull;Keep out of the reach and sight of children.</p><p>&bull;Do not use after the expiry date (EXP) which is stated on the carton.</p><p>&bull;Unopened vial: Store below 30&deg;C.</p><p>&bull;Reconstituted solution: The product should be used immediately. When prepared as directed, chemical and physical in-use stability of reconstituted solutions of gemcitabine were demonstrated for 24 hours at 30&deg;C. Further dilution by a healthcare provider may be done. Solutions of reconstituted gemcitabine should not be refrigerated, as crystallization may occur.</p><p>&bull;This medicine is for single use only; any unused solution should be discarded under the local requirements.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substance is gemcitabine. Each vial contains 200 or 1000 mg of gemcitabine (as gemcitabine hydrochloride).</p><p>The other ingredients are mannitol (E421), sodium acetate, hydrochloric acid and sodium hydroxide.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Gebtin® is a white to off-white powder, for solution for infusion in a vial. Each vial contains 200 or 1000 mg of gemcitabine. Each pack of Gebtin® contains 1 vial.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>MS Pharma Saudi,</p><p>Riyadh, Kingdome Saudi Arabia.</p><p>&nbsp;info-ksa@mspharma.com</p><p>&nbsp;</p><p><strong>Manufacturing by</strong></p><p>Jiangsu Hengrui Medicine Co., Ltd &amp; Jiangsu Hansoh Pharmaceutical Group Co., Ltd - china for MS Pharma - Saudi</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                May,2021
SPM-14-0012  

            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">ينتمي <strong>جيبتن</strong> إلى مجموعة من الأدوية تسمى &laquo; الأدوية السامة للخلايا &raquo;. هذه</p><p dir="RTL">الأدوية تقتل الخلايا في مرحلة الانقسام، بما في ذلك الخلايا السرطانية.</p><p dir="RTL">يمكن إعطاء <strong>جيبتن</strong> بمفرده أو بالاشتراك مع أدوية أخرى مضادة للسرطان،</p><p dir="RTL">وهذا يتوقف على نوع السرطان.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>يستخدم جيبتن في علاج أنواع السرطانات التالية:</strong></p><p dir="RTL">&bull;سرطان الرئة ذو الخلايا غير الصغيرة ( NSCLC )، بمفرده أو مع سيسبلاتين</p><p dir="RTL">&bull;سرطان البنكرياس.</p><p dir="RTL">&bull; سرطان الثدي، جنبا إلى جنب مع باكليتاكسيل.</p><p dir="RTL">&bull;سرطان المبيض، جنبا إلى جنب مع كاربوبلاتين.</p><p dir="RTL">&bull;سرطان المثانة، جنبا إلى جنب مع سيسبلاتين.</p><p dir="RTL"><strong>&nbsp;</strong></p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>يجب عدم اعطاء جيبتن :</strong></p><p dir="RTL">-إذا كنت تعاني من حساسية (فرط الحساسة) لمادة جيمسيتابين أو لأي من</p><p dir="RTL">المكونات الأخرى من <strong>جيبتن</strong> .</p><p dir="RTL">-إذا كنت ترضعين رضاعة طبيعية</p><p dir="RTL"><strong>خذ عناية خاصة مع جيبتن:</strong> قبل عملية التسريب الأولى، سنحصل على</p><p dir="RTL">عينات من دمك لتقييم ما إذا كان لديك وظائف كافية للكلى والكبد. قبل كل عملية</p><p dir="RTL">تسريب، سنحصل على عينات من دمك لتقييم ما إذا كان لديك ما يكفي من خلايا</p><p dir="RTL">الدم لتلقي <strong>جيبتن</strong>. قد يقرر طبيبك تغيير الجرعة أو التأخير في علاجك وفقًا</p><p dir="RTL">لحالتك العامة وإذا كانت أعداد خلايا الدم لديك منخفضة جدًا. بشكل دوري سيكون</p><p dir="RTL">لديك عينات من دمك لتقييم وظائف الكلى والكبد.</p><p dir="RTL">&nbsp;</p><p dir="RTL">من فضلك أخبر طبيبك إذا: لديك، أو سبق أن كان لديك مرض الكبد، وأمراض</p><p dir="RTL">القلب أو أمراض الأوعية الدموية.</p><p dir="RTL">&bull;لديك مؤخرا، أو سيكون لديك علاج إشعاعي،</p><p dir="RTL">&bull;لقد تم تلقيحك مؤخرًا</p><p dir="RTL">&bull;تطور لديك صعوبات في التنفس أو تشعر بضعيف الشديد و كنت شاحب (قد</p><p dir="RTL">يكون إشارة لحدوث فشل كلوي).</p><p dir="RTL">ينصح الرجال بعدم التخصيب خلال فترة تصل إلى 6 أشهر بعد العلاج مع</p><p dir="RTL"><strong>جيبتن</strong>. إذا كنت تريد حدوث التخصيب أثناء فترة العلاج أو خلال الستة أشهر</p><p dir="RTL">التالية للعلاج، فاستشر طبيبك أو الصيدلي. قد ترغب في طلب المشورة بشأن</p><p dir="RTL">تخزين الحيوانات المنوية قبل بدء العلاج.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>تناول أدوية أخرى</strong></p><p dir="RTL">من فضلك أخبر طبيبك أو صيدلي المستشفى إذا كنت تتناول أو أخذت مؤخرًا</p><p dir="RTL">أي أدوية أخرى، بما في ذلك اللقاحات والأدوية التي تم الحصول عليها بدون</p><p dir="RTL">وصفة طبية.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>الحمل والرضاعة الطبيعية</strong></p><p dir="RTL">إذا كنت حاملاً أو تفكري في الحمل، أخبري طبيبك. يجب تجنب استخدام</p><p dir="RTL"><strong>جيبتن</strong> أثناء الحمل. طبيبك سوف يناقش معك المخاطر المحتملة لأخذ</p><p dir="RTL"><strong>جيبتن</strong> خلال فترة الحمل.</p><p dir="RTL">إذا كنت تقومين بالرضاعة الطبيعية، أخبري طبيبك. يجب عليك التوقف عن</p><p dir="RTL">الرضاعة الطبيعية خلال العلاج مع <strong>جيبتن</strong> .</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>القيادة واستخدام الآلات</strong></p><p dir="RTL">قد يجعلك <strong>جيبتن</strong> تشعر بالنعاس، خاصة إذا كنت تشرب الكحول. لا تقود</p><p dir="RTL">السيارة أو تستخدم آلات حتى تتأكد من أن العلاج مع <strong>جيبتن</strong> لا يجعلك تشعر</p><p dir="RTL">بالنعاس.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>معلومات هامة حول بعض مكونات جيبتن</strong></p><p dir="RTL">يحتوي <strong>جيبتن</strong> على 3.5 ملغم (&gt; 1 ملمول ) من الصوديوم في كل عبوة</p><p dir="RTL">200 ملغم و 17.5 ملغم (&gt; 1 ملمول ) من الصوديوم في كل عبوة 1000</p><p dir="RTL">ملغم. لتأخذ بعين الاعتبار من قبل المرضى الذين يحصلون على نظام غذائي</p><p dir="RTL">مسيطر على الصوديوم.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">الجرعة الموصى بها من <strong>جيبتن</strong> هي 1000 - 1250 ملغم لكل متر مربع من</p><p dir="RTL">مساحة سطح الجسم. يتم قياس الطول والوزن الخاصين بك لحساب مساحة سطح</p><p dir="RTL">الجسم. سيستخدم طبيبك هذه المساحة السطحية للجسم لحساب الجرعة المناسبة</p><p dir="RTL">لك. قد يتم تعديل هذه الجرعة، أو قد يتأخر العلاج اعتمادًا على عدد خلايا الدم</p><p dir="RTL">وعلى حالتك العامة.</p><p dir="RTL">يعتمد مدى تكرار حصولك على <strong>جيبتن</strong> على نوع السرطان الذي يتم علاجه.</p><p dir="RTL">سيقوم صيدلي المستشفى أو الطبيب بحل مسحوق جيمسيتابين قبل إعطائه لك.</p><p dir="RTL">سوف تتلقى دائما <strong>جيبتن</strong>عن طريق التسريب في واحدة من عروقك. سيستمر</p><p dir="RTL">التسريب حوالي 30 دقيقة.</p><p dir="RTL">إذا كان لديك المزيد من الأسئلة حول استخدام هذا المنتج اسأل طبيبك أو الصيدلي.</p><p dir="RTL"><strong>&nbsp;</strong></p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل جميع الأدوية، يمكن أن يسبب <strong>جيبتن</strong> آثار جانبية، على الرغم من عدم</p><p dir="RTL">حدوثها في الجميع.</p><p dir="RTL">يتم تعريف تكرار الآثار الجانبية الملاحظة على النحو التالي:</p><p dir="RTL">&bull; شائعة جدًا: تؤثر في أكثر من مستخدم واحد من كل 10 مستخدمين</p><p dir="RTL">&bull; شائعة: تؤثر على عدد يتراوح من 1 إلى 10 مستخدمين من كل 100 مستخدم</p><p dir="RTL">&bull;غير شائعة: تؤثر على 1 إلى 10 مستخدمين من كل 1000 مستخدم</p><p dir="RTL">&bull;نادرة: تؤثر على 1 إلى 10 مستخدمين من كل 10000 مستخدم</p><p dir="RTL">&bull;نادرة جدًا: تؤثر على أقل من مستخدم واحد من كل 10000 مستخدم</p><p dir="RTL">&bull;غير معروف: لا يمكن تقدير التكرار من البيانات المتاحة</p><p dir="RTL">يجب عليك الاتصال بالطبيب على الفور إذا لاحظت أيًا مما يلي:</p><p dir="RTL">&bull; حمى أو عدوى (شائعة): إذا كانت درجة حرارة 38 درجة مئوية أو أكثر، أو</p><p dir="RTL">التعرق أو علامات أخرى من العدوى (لانه من الشائع جدا أن تمتلك خلايا دم</p><p dir="RTL">بيضاء أقل من المعتاد).</p><p dir="RTL">&bull;عدم انتظام ضربات القلب (تكرار غير معروف).</p><p dir="RTL">&bull;ألم أو احمرار أو تورم أو تقرحات في الفم (شائعة).</p><p dir="RTL">&bull;ردود الفعل التحسسية: إذا أصبح لديك طفح جلدي (شائع جدا) / حكة (شائعة) أو</p><p dir="RTL">حمى ( شائعة جدا ).</p><p dir="RTL">&bull;التعب، والشعور بالإغماء، وصعوبة التنفس أو إذا كنت شاحبا (حيث أنه لديك</p><p dir="RTL">كمية الهيموغلوبين أقل من المعتاد).</p><p dir="RTL">&bull;نزيف من اللثة أو الأنف أو الفم أو أي نزيف لا يتوقف، بول ذو لون أحمر أو</p><p dir="RTL">وردي. كدمات غير متوقعة (لانه من الشائع جدا أن تمتلك صفائح دموية أقل</p><p dir="RTL">من العادي).</p><p dir="RTL">&bull;صعوبة التنفس (لانه من الشائع جدا أن تمتلك صعوبة تنفس معتدلة بعد تسريب</p><p dir="RTL">جيمسيتابين للحقن، ولكن غير شائع أو نادرا ما يحدث مشاكل أشد في الرئة).</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>قد تتضمن الآثار الجانبية مع جيبتن : </strong></p><p dir="RTL"><strong>تأثيرات جانبية شائعة جدًا</strong></p><p dir="RTL">&bull;مستوى الهيموجلوبين منخفض ( فقر الدم)</p><p dir="RTL">&bull;انخفاض خلايا الدم البيضاء</p><p dir="RTL">&bull;انخفاض عدد الصفائح الدموية</p><p dir="RTL">&bull; صعوبة في التنفس</p><p dir="RTL">&bull;قيء</p><p dir="RTL">&bull;غثيان</p><p dir="RTL">&bull;الطفح الجلدي - طفح جلدي تحسسي، والحكة في كثير من الأحيان</p><p dir="RTL">&bull;تساقط الشعر</p><p dir="RTL">&bull; مشاكل الكبد: وجدت من خلال نتائج غير طبيعية في اختبار الدم</p><p dir="RTL">&bull;دم في البول</p><p dir="RTL">&bull;اختبارات البول غير طبيعية: بروتين في البول</p><p dir="RTL">&bull;أعراض الانفلونزا بما في ذلك الحمى</p><p dir="RTL">&bull;وذمة (تورم في الكاحلين والأصابع والقدمين والوجه)</p><p dir="RTL"><strong>الآثار الجانبية الشائعة</strong></p><p dir="RTL">&bull;حمى مصحوبة بانخفاض عدد خلايا الدم البيضاء (قلة العدلات الحموية )</p><p dir="RTL">&bull;فقدان الشهية (ضعف الشهية)</p><p dir="RTL">&bull;صداع</p><p dir="RTL">&bull;أرق</p><p dir="RTL">&bull;النعاس</p><p dir="RTL">&bull;سعال</p><p dir="RTL">&bull;سيلان الأنف</p><p dir="RTL">&bull;امساك</p><p dir="RTL">&bull;الإسهال</p><p dir="RTL">&bull;ألم أو احمرار أو تورم أو تقرحات في الفم</p><p dir="RTL">&bull;الحكة</p><p dir="RTL">&bull;التعرق</p><p dir="RTL">&bull;ألم العضلات</p><p dir="RTL">&bull;آلام الظهر</p><p dir="RTL">&bull;الحمى</p><p dir="RTL">&bull;الضعف</p><p dir="RTL">&bull;القشعريرة</p><p dir="RTL"><strong>آثار جانبية غير شائعة</strong></p><p dir="RTL">&bull;التهاب رئوي خلالي (تندب الأكياس الهوائية للرئة) تشنج الشعب الهوائية (أزيز)</p><p dir="RTL">&bull;صورة شعاعية / مسح للصدر غير طبيعي (تندب من الرئتين)</p><p dir="RTL"><strong>آثار جانبية نادرة</strong></p><p dir="RTL">&bull;نوبة قلبية (احتشاء عضلة القلب)</p><p dir="RTL">&bull;انخفاض ضغط الدم</p><p dir="RTL">&bull;تقشر الجلد، تقرح أو تشكيل بثور</p><p dir="RTL">&bull;ردود فعل في موقع الحقن</p><p dir="RTL"><strong>آثار جانبية نادرة جدا</strong></p><p dir="RTL">&bull;زيادة عدد الصفائح الدموية</p><p dir="RTL">&bull;رد فعل تحسسي (فرط الحساسية الشديد / رد فعل تحسسي)</p><p dir="RTL">&bull;تخلخل الجلد وتقرحات جلدية شديدة</p><p dir="RTL"><strong>الآثار الجانبية مع تكرار غير معروف</strong></p><p dir="RTL">&bull;عدم انتظام ضربات القلب</p><p dir="RTL">&bull;متلازمة الضائقة التنفسية عند البالغين (التهاب رئوي حاد يسبب قصور في</p><p dir="RTL">الجهاز التنفسي)</p><p dir="RTL">&bull; المعاودة الإشعاعية&nbsp; (طفح جلدي مثل حروق الشمس الحادة) والذي يمكن أن يحدث على الجلد الذي سبق أن تعرض للعلاج الإشعاعي.</p><p dir="RTL">&bull; سوائل في الرئتين</p><p dir="RTL">&bull;&nbsp; التسمم الاشعاعي - تندب من الحويصلات الهوائية في الرئة والذي يرتبط مع</p><p dir="RTL">العلاج الاشعاعي</p><p dir="RTL">&bull;التهاب القولون الافقاري (التهاب بطانة الأمعاء الغليظة، الناجمة عن انخفاض</p><p dir="RTL">إمدادات الدم)</p><p dir="RTL">&bull;فشل القلب</p><p dir="RTL">&bull;فشل كلوي</p><p dir="RTL">&bull;الغرغرينا من الأصابع أو أصابع القدم</p><p dir="RTL">&bull;ضرر خطير في الكبد ، ويتضمن فشل الكبد</p><p dir="RTL">&bull;السكتة الدماغية</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد يكون لديك أي من هذه الأعراض و / أو الحالات. يجب عليك إخبار طبيبك في</p><p dir="RTL">أقرب وقت ممكن عندما تبدأ في مواجهة أي من هذه الآثار الجانبية.</p><p dir="RTL">إذا كنت قلقًا بشأن أي آثار جانبية، تحدث إلى طبيبك.</p><p dir="RTL">إذا أصبحت أي من الآثار الجانبية خطيرة، أو إذا لاحظت أي آثار جانبية لم تذكر</p><p dir="RTL">في هذه النشرة، يرجى إخبار طبيبك.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يُحفظ بعيدا عن متناول ونظر الأطفال.</p><p dir="RTL">&bull;لا يستخدم بعد انتهاء تاريخ الانتهاء ( EXP ) المكتوب على العبوة.</p><p dir="RTL">&bull;عبوة غير مفتوحة: تحفظ بدرجة حرارة أقل من 30 درجة مئوية.</p><p dir="RTL">&bull;المحلول المعدّ: يجب استخدام المنتج على الفور. عندما تم تحضيره وفقًا</p><p dir="RTL">للتوجيهات، تم إثبات استقرار المواد الكيميائية والفيزيائية عند الاستخدام للمحلول</p><p dir="RTL">لمدة 24 ساعة في درجة حرارة 30 درجة مئوية. يمكن اجراء مزيد من التخفيف</p><p dir="RTL">من قبل مقدم الرعاية الصحية. المحلول المعد من جيمسيتابين يجب عدم تبريده،</p><p dir="RTL">، قد يحدث التبلور.</p><p dir="RTL">&bull;هذا الدواء للاستخدام الفردي فقط؛ يجب التخلص من أي محلول غير مستخدم</p><p dir="RTL">حسب المتطلبات المحلية.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">المادة الفعالة هي جيمسيتابين. تحتوي كل عبوة على 200 أو 1000 ملغم من</p><p dir="RTL">الجيمسيتابين (على هيئة جيمسيتابين هيدروكلوريد).</p><p dir="RTL">المكونات الأخرى هي مانيتول ( E421 )، وأسيتات الصوديوم، وحمض</p><p dir="RTL">الهيدروكلوريك وهيدروكسيد الصوديوم.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>جيبتن</strong> هو مسحوق أبيض إلى بيج، للحل للتسريب في عبوة. كل عبوة</p><p dir="RTL">تحتوي على 200 أو 1000 ملغم من الجيمسيتابين. كل علبة من <strong>جيبتن</strong></p><p dir="RTL">تحتوي على عبوة واحدة.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">ام اس فارما السعودية</p><p dir="RTL">الرياض - المملكة العربية السعودية</p><p dir="RTL">info-ksa@mspharma.com</p><p dir="RTL"><strong>يصنع بواسطة</strong></p><p dir="RTL">شركة أدوية جيانغسو هينجريي المحدودة وشركة جيانغسوهانسو المحدودة - الصين لصالح إم إس فارما - السعودية</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            مايو ، 2021
SPM-14-0012  

        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Gebtin 200mg Lyophilized Powder for Injection
Gebtin 1g Lyophilized Powder for Injection

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                One vial contains gemcitabine hydrochloride, equivalent to 200 mg gemcitabine.
One vial contains gemcitabine hydrochloride, equivalent to 1 g gemcitabine.
After reconstitution, the solution contains 38 mg/ml gemcitabine (as hydrochloride).
Excipients 
Each 200 mg vial contains approximately 3.5 mg (0.15 mmol) sodium.
Each 1 g vial contains approximately 17.5 mg (0.75 mmol) sodium.
For a full list of excipients, see section 6.1 

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Lyophilized Powder for Injection 
White to off-white plug or powder.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Bladder Cancer:</strong></p><p>Locally advanced or metastatic bladder cancer, in combination with cisplatin.</p><p><strong>Pancreatic Cancer:</strong></p><p>Locally advanced or metastatic adenocarcinoma of the pancreas.</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>Non-Small Cell Lung Cancer:</strong></p><p>First-line treatment of patients with locally advanced or metastatic non-small cell lung cancer, in combination with cisplatin. Gemcitabine monotherapy can be considered in elderly patients or those with performance status 2.</p><p><strong>Ovarian Cancer:</strong></p><p>Locally advanced or metastatic epithelial ovarian carcinoma, in combination with carboplatin, in patients with relapsed disease following a recurrence-free interval of at least 6 months after platinum-based, first line therapy.</p><p><strong>Breast Cancer:</strong></p><p>Unresectable, locally recurrent or metastatic breast cancer, in combination with paclitaxel, in patients experiencing a relapse after adjuvant/neoadjuvant chemotherapy. The preceding chemotherapy should have included an anthracycline, unless clinically contraindicated.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Route of administration:</p><p>For intravenous infusion, following reconstitution. Upon reconstitution a colourless or slightly yellow solution is produced.</p><p><strong>Gemcitabine should only be prescribed by a physician qualified in the use of anti-cancer chemotherapy.</strong></p><p><strong>Bladder cancer (combination therapy):</strong></p><p><em>Adults:</em> The recommended dose for gemcitabine is 1000 mg/m<sup>2</sup>, given as a 30 minute infusion. The dose should be given on days 1, 8, and 15 of each 28 day cycle in combination with cisplatin. Cisplatin is given at a recommended dose of 70 mg/m<sup>2</sup> on day 1 following gemcitabine, or day 2 of each 28 day cycle. This four week cycle is then repeated. Dosage reduction with each cycle or within a cycle may be applied, based upon the amount of toxicity experienced by the patient.</p><p><strong>Pancreatic Cancer:</strong></p><p><em>Adults: </em>The recommended dose of gemcitabine is 1000 mg/m<sup>2</sup>, given by 30 minute intravenous infusion. This should be repeated once weekly for up to 7 weeks, followed by a one week rest period. Subsequent cycles should consist of gemcitabine infusions once weekly for 3 consecutive weeks out of every four weeks. Dosage reduction with each cycle or within a cycle may be applied, based upon the amount of toxicity experienced by the patient.</p><p><strong>Non-small cell lung cancer (monotherapy):</strong></p><p><em>Adults:</em> The recommended dose of gemcitabine is 1000 mg/m<sup>2</sup>, given by 30 minute intravenous infusion. This should be repeated once weekly for three weeks, followed by a one week rest period. This four-week cycle is then repeated. Dosage reduction with each cycle or within a cycle may be applied, based upon the amount of toxicity experienced by the patient.</p><p><strong>Non-small cell lung cancer (combination therapy):</strong></p><p><em>Adults:</em> The recommended dose of gemcitabine is 1250 mg/m<sup>2</sup>, given by 30 minute intravenous infusion, on days 1 and 8 of each 21 day cycle. Dosage reduction with each cycle or within a cycle may be applied, based upon the amount of toxicity experienced by the patient.</p><p>Cisplatin has been used at doses between 75-100 mg/m<sup>2</sup> once every 3 weeks.</p><p><strong>Ovarian cancer (combination therapy):</strong></p><p>The recommended dose of gemcitabine, when used in combination with carboplatin, is 1000 mg/m<sup>2</sup>, given by 30 minute intravenous infusion on days 1 and 8 of each 21 day cycle. After gemcitabine, carboplatin will be given on day 1, consistent with a target Area Under Curve (AUC) of 4.0mg/ml/min. Dosage reduction with each cycle or within a cycle may be applied, based upon the amount of toxicity experienced by the patient.</p><p><strong>Breast cancer (combination therapy):</strong></p><p><em>Adults: </em>It is recommended that gemcitabine is used together with paclitaxel according to the following procedure:</p><p>Paclitaxel (175 mg/m<sup>2</sup>) is intravenously infused over 3 hours on day 1, followed by gemcitabine (1250 mg/m<sup>2</sup>) intravenously infused for 30 minutes on days 1 and 8 of each 21 day treatment cycle. Dosage reduction with each cycle or within a cycle may be applied based upon the amount of toxicity experienced by the patient. The absolute granulocyte count should be at least 1.5 x 10<sup>9</sup>/l before treatment with the gemcitabine + paclitaxel combination.</p><p><strong><u>Monitoring for toxicity and dose modification due to toxicity</u> </strong></p><p><strong>Dosage adjustment due to non haematological toxicity:</strong></p><p>Periodic physical examination and checks of renal and hepatic function should be made to detect non-haematological toxicity. Dosage reduction with each cycle or within a cycle may be applied, based upon the amount of toxicity experienced by the patient. In general, for severe (Grade 3 or 4) non-haematological toxicity, except nausea/vomiting, therapy with gemcitabine should be withheld or decreased depending on the judgement of the treating physician. Doses should be withheld until toxicity has been resolved.</p><p>For cisplatin, carboplatin, and paclitaxel dosage adjustment in combination therapy, please refer to the corresponding Summary of Product Characteristics.</p><p><strong>Dosage adjustment in the presence of haematological toxicity:</strong></p><p><em>Initiation of a cycle</em></p><p>For all indications, patients must be monitored before each dose for platelet and granulocyte counts. Patients should have an absolute granulocyte count of at least 1,500 (x10<sup>6</sup>/l) and a platelet count of 100,000 (x10<sup>6</sup>/l) prior to the administration of a cycle.</p><p><em>Within a cycle</em></p><p>Dose modifications of gemcitabine within a cycle should be performed according to the following tables:</p><table border="1" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td colspan="4" style="vertical-align:top"><p><strong>Dose modification of gemcitabine within a cycle for bladder cancer, pancreatic cancer, and NSCLC, given in monotherapy or in combination with cisplatin</strong></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Absolute Granulocyte Count</strong></p><p><strong>(x 10<sup>9</sup>/l)</strong></p></td><td style="vertical-align:top"><p><strong>Platelet Count</strong></p><p><strong>(x 10<sup>9</sup>/l)</strong></p></td><td style="vertical-align:top"><p><strong>% of Total Dose</strong></p></td></tr><tr><td style="vertical-align:top"><p>&gt; 1</p></td><td style="vertical-align:top"><p>and</p></td><td style="vertical-align:top"><p>&gt;100</p></td><td style="vertical-align:top"><p>100</p></td></tr><tr><td style="vertical-align:top"><p>0.5-1</p></td><td style="vertical-align:top"><p>or</p></td><td style="vertical-align:top"><p>50-100</p></td><td style="vertical-align:top"><p>75</p></td></tr><tr><td style="vertical-align:top"><p>&lt; 0.5</p></td><td style="vertical-align:top"><p>or</p></td><td style="vertical-align:top"><p>&lt;50</p></td><td style="vertical-align:top"><p>Withhold*</p></td></tr></tbody></table><p>*Withheld treatment will not be reinstated within a cycle before the absolute granulocyte count reaches at least 0.5(x 10<sup>9</sup>/l) and the platelet count reaches 50 (x 10<sup>9</sup>/l).</p><table border="1" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td colspan="4" style="vertical-align:top"><p><strong>Dose modification of gemcitabine within a cycle for ovarian cancer, given in combination with carboplatin</strong></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Absolute Granulocyte Count</strong></p><p><strong>(x 10<sup>9</sup>/l)</strong></p></td><td style="vertical-align:top"><p><strong>Platelet Count</strong></p><p><strong>(x 10<sup>9</sup>/l)</strong></p></td><td style="vertical-align:top"><p><strong>% of Total Dose</strong></p></td></tr><tr><td style="vertical-align:top"><p>&gt;1.5</p></td><td style="vertical-align:top"><p>and</p></td><td style="vertical-align:top"><p>&gt;100</p></td><td style="vertical-align:top"><p>100</p></td></tr><tr><td style="vertical-align:top"><p>1-1.5</p></td><td style="vertical-align:top"><p>or</p></td><td style="vertical-align:top"><p>75-100</p></td><td style="vertical-align:top"><p>50</p></td></tr><tr><td style="vertical-align:top"><p>&lt;1</p></td><td style="vertical-align:top"><p>or</p></td><td style="vertical-align:top"><p>&lt;75</p></td><td style="vertical-align:top"><p>Withhold*</p></td></tr></tbody></table><p>*Withheld treatment will not be reinstated within a cycle. Treatment will start on day 1 of the next cycle once the absolute granulocyte count reaches at least 1.5(x 10<sup>9</sup>/l) and the platelet count reaches 100 (x 10<sup>9</sup>/l)</p><table border="1" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td colspan="4" style="vertical-align:top"><p><strong>Dose modification of gemcitabine within a cycle for breast cancer, given in combination with paclitaxel</strong></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Absolute Granulocyte Count</strong></p><p><strong>(x 10<sup>9</sup>/l)</strong></p></td><td style="vertical-align:top"><p><strong>Platelet Count</strong></p><p><strong>(x 10<sup>9</sup>/l)</strong></p></td><td style="vertical-align:top"><p><strong>% of Total Dose</strong></p></td></tr><tr><td style="vertical-align:top"><p>&ge;1.2</p></td><td style="vertical-align:top"><p>and</p></td><td style="vertical-align:top"><p>&gt;75</p></td><td style="vertical-align:top"><p>100</p></td></tr><tr><td style="vertical-align:top"><p>1-&lt;1.2</p></td><td style="vertical-align:top"><p>or</p></td><td style="vertical-align:top"><p>50-75</p></td><td style="vertical-align:top"><p>75</p></td></tr><tr><td style="vertical-align:top"><p>0.7-&lt;1</p></td><td style="vertical-align:top"><p>and</p></td><td style="vertical-align:top"><p>&ge;50</p></td><td style="vertical-align:top"><p>50</p></td></tr><tr><td style="vertical-align:top"><p>&lt;0.7</p></td><td style="vertical-align:top"><p>or</p></td><td style="vertical-align:top"><p>&lt;50</p></td><td style="vertical-align:top"><p>Withhold*</p></td></tr></tbody></table><p>*Withheld treatment will not be reinstated within a cycle. Treatment will start on day 1 of the next cycle once the absolute granulocyte count reaches at least 1.5 (x 10<sup>9</sup>/l) and the platelet count reaches 100 (x 10<sup>9</sup>/l).</p><p><strong>Dose adjustment due to haematological toxicity in subsequent cycles, for all indications</strong></p><p>The gemcitabine dose should be reduced to 75% of the original cycle initiation dose, in the case of the following haematological toxicities:</p><p>&bull; Absolute granulocyte count &lt; 0.5 x 10<sup>9</sup>/l for more than 5 days</p><p>&bull; Absolute granulocyte count &lt; 0.1 x 10<sup>9</sup>/l for more than 3 days</p><p>&bull; Febrile neutropaenia</p><p>&bull; Platelets &lt;25 x 10<sup>9</sup>/l</p><p>&bull; Cycle delay of more than one week due to toxicity</p><p><strong>Method of administration</strong></p><p>Gemcitabine is tolerated well during infusion and may be administered ambulant. If extravasation occurs, generally the infusion must be stopped immediately and started again in another blood vessel. The patient should be monitored carefully after the administration.</p><p>For instructions on reconstitution, see section 6.6</p><p><strong><u>Special Populations</u> </strong></p><p><strong>Patients with hepatic or renal impairment: </strong></p><p>Gemcitabine should be used with caution in patients with hepatic or renal impairment as there is insufficient information from clinical studies to allow for clear dose recommendations for these patient populations (see sections 4.4 and 5.2).</p><p><strong>Elderly population (&gt;65 years): </strong></p><p>Gemcitabine has been well tolerated in patients over the age of 65. There is no evidence to suggest that dose adjustments, other than those already recommended for all patients, are necessary in the elderly (see section 5.2).</p><p><strong>Paediatric population (&lt;18 years): </strong></p><p>Gemcitabine is not recommended for use in children under 18 years of age due to insufficient data on safety and efficacy.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to gemcitabine or to any of the excipients
Breast-feeding (see section 4.6)

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Prolongation of the infusion time and increased dosing frequency have been shown to increase toxicity.</p><p><strong>Haematological toxicity</strong></p><p>Gemcitabine can suppress bone marrow function as manifested by leucopaenia, thrombocytopaenia, and anaemia.</p><p>Patients receiving gemcitabine should be monitored prior to each dose for platelet, leucocyte and granulocyte counts. Suspension or modification of therapy should be considered when drug-induced bone marrow depression is detected (see section 4.2). However, myelosuppression is short lived and usually does not result in dose reduction and rarely in discontinuation.</p><p>Peripheral blood counts may continue to deteriorate after gemcitabine administration has been</p><p>stopped. In patients with impaired bone marrow function, the treatment should be started with caution. As with other cytotoxic treatments, the risk of cumulative bone-marrow suppression must be considered when gemcitabine treatment is given together with other chemotherapy.</p><p><strong>Hepatic impairment </strong></p><p>Administration of gemcitabine to patients with concurrent liver metastases or a pre-existing medical history of hepatitis, alcoholism or cirrhosis of the liver may result in exacerbation of the underlying liver impairment.</p><p>Laboratory evaluation of renal and hepatic function (including virological tests) should be performed periodically.</p><p>Gemcitabine should be used with caution in patients with hepatic insufficiency or with impaired renal function as there is insufficient information from clinical studies to allow clear dose recommendation for this patient population (see section 4.2).</p><p><strong>Concomitant radiotherapy</strong></p><p>Concomitant radiotherapy (given together or &le;7 days apart): Toxicity has been reported (see section 4.5 for details and recommendations for use).</p><p><strong>Live vaccinations</strong></p><p>Yellow fever vaccine and other live attenuated vaccines are not recommended in patients treated with gemcitabine (see section 4.5).</p><p><strong>Posterior reversible encephalopathy syndrome</strong></p><p>Reports of posterior reversible encephalopathy syndrome (PRES) with potentially severe consequences have been reported in patients receiving gemcitabine as single agent or in combination with other chemotherapeutic agents. Acute hypertension and seizure activity were reported in most gemcitabine patients experiencing PRES, but other symptoms such as headache, lethargy, confusion and blindness could also be present. Diagnosis is optimally confirmed by magnetic resonance imaging (MRI). PRES was typically reversible with appropriate supportive measures. Gemcitabine should be permanently discontinued and supportive measures implemented, including blood pressure control and anti-seizure therapy, if PRES develops during therapy.</p><p><strong>Cardiovascular</strong></p><p>Due to the risk of cardiac and/or vascular disorders with gemcitabine, particular caution must be exercised with patients presenting a history of cardiovascular events.</p><p><em>Capillary leak syndrome</em></p><p>Capillary leak syndrome has been reported in patients receiving gemcitabine as single agent or in combination with other chemotherapeutic agents (see section 4.8). The condition is usually treatable if recognised early and managed appropriately, but fatal cases have been reported. The condition involves systemic capillary hyperpermeability during which fluid and proteins from the intravascular space leak into the interstitium. The clinical features include generalised oedema, weight gain, hypoalbuminaemia, severe hypotension, acute renal impairment and pulmonary oedema. Gemcitabine should be discontinued and supportive measures implemented if capillary leak syndrome develops during therapy. Capillary leak syndrome can occur in later cycles and has been associated in the literature with adult respiratory distress syndrome.</p><p><strong>Pulmonary</strong></p><p>Pulmonary effects, sometimes severe (such as pulmonary oedema, interstitial pneumonitis, or adult respiratory distress syndrome (ARDS), have been reported in association with gemcitabine therapy. The aetiology of these effects is unknown. If such effects develop, consideration should be given to discontinuing gemcitabine therapy. Early use of supportive care measures may help ameliorate the condition.</p><p><strong>Renal</strong></p><p>Clinical findings consistent with the haemolytic uraemic syndrome (HUS) were rarely reported in patients receiving gemcitabine (see section 4.8). HUS is a life-threatening disease. Treatment should be discontinued at the first signs of any evidence of micro-angiopathic haemolytic anaemia, such as rapidly falling haemoglobin levels with concurrent thrombocytopenia, elevation of serum bilirubin, serum creatinine, blood urea nitrogen or lactate dehydrogenase (LDH). Renal failure may not be reversible with discontinuation of therapy, and dialysis may be required.</p><p><strong>Fertility</strong></p><p>In fertility studies, gemcitabine caused hypospermatogenesis in male mice (see section 5.3). Therefore, men being treated with gemcitabine are advised not to father a child during and up to 6 months after treatment and to seek further advice regarding cryoconservation of sperm prior to treatment because of the possibility of infertility due to therapy with gemcitabine (see section 4.6).</p><p><strong>Sodium</strong></p><p>Gebtin 200 mg contains 3.5 mg (0.15 mmol) sodium per vial. This should be taken into consideration by patients on a sodium-controlled diet.</p><p>Gebtin 1 g contains 17.5 mg (0.75 mmol) sodium per vial. This should be taken into consideration by patients on a sodium-controlled diet.</p><p>Gemcitabine 1 g contains 35 mg (1.5 mmol) sodium per vial. This should be taken into consideration by patients on a sodium-controlled diet.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No specific interaction studies have been performed (see section 5.2)</p><p><strong>Radiotherapy</strong></p><p><em>Concurrent (given together or &le; 7 days apart)</em> - Toxicity associated with this multimodality therapy is dependent on many different factors, including dose of gemcitabine, frequency of gemcitabine administration, dose of radiation, radiotherapy planning technique, the target tissue, and target volume.</p><p>Pre-clinical and clinical studies have shown that gemcitabine has radiosensitising activity. In a single trial, where gemcitabine at a dose of 1,000 mg/m<sup>2 </sup>was administered concurrently for up to 6 consecutive weeks with therapeutic thoracic radiation to patients with non-small cell lung cancer, significant toxicity in the form of severe, and potentially life threatening mucositis, especially oesophagitis, and pneumonitis was observed, particularly in patients receiving large volumes of radiotherapy [median treatment volumes 4,795 cm<sup>3</sup>]. Studies done subsequently have suggested that it is feasible to administer gemcitabine at lower doses with concurrent radiotherapy with predictable toxicity, such as a phase II study in non-small cell lung cancer, where thoracic radiation doses of 66 Gy were applied concomitantly with an administration with gemcitabine (600 mg/m<sup>2</sup>, four times) and cisplatin (80 mg/m<sup>2</sup> twice) during 6 weeks. The optimum regimen for safe administration of gemcitabine with therapeutic doses of radiation has not yet been determined in all tumour types.</p><p><em>Non-concurrent (given &gt;7 days apart) -</em> Available information does not indicate any enhanced toxicity when gemcitabine is administered more than 7 days before or after radiation, other than radiation recall. Data suggest that gemcitabine can be started after the acute effects of radiation have resolved or at least one week after radiation.</p><p>Radiation injury has been reported on targeted tissues (e.g. oesophagitis, colitis, and pneumonitis) in association with both concurrent and non-concurrent use of gemcitabine.</p><p><strong>Others</strong></p><p>Yellow fever and other live attenuated vaccines are not recommended due to the risk of systemic, possibly fatal, disease, particularly in immunosuppressed patients.</p><p><strong><u>&nbsp;</u></strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Pregnancy: </strong></p><p>There are no adequate data from the use of gemcitabine in pregnant patients. Studies in animals have shown reproductive toxicity (see section 5.3). Based on results from animal studies and the mechanism of action of gemcitabine, this substance should not be used during pregnancy, unless clearly necessary. Women should be advised not to become pregnant during treatment with gemcitabine and to warn their attending physician immediately, should this occur.</p><p><strong>Breast feeding:</strong></p><p>It is not known whether gemcitabine is excreted in human milk and adverse events on the suckling child cannot be excluded. Breast-feeding must be discontinued during gemcitabine therapy.</p><p><strong>Fertility:</strong></p><p>In fertility studies, gemcitabine caused hypospermatogenesis in male mice (see section 5.3). Therefore, men being treated with gemcitabine are advised not to father a child during and up to 6 months after treatment and to seek further advice regarding cryoconservation of sperm prior to treatment because of the possibility of infertility due to therapy with gemcitabine</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No studies on the effects on the ability to drive and use machines have been performed. However, gemcitabine has been reported to cause mild to moderate somnolence, especially in combination with alcohol consumption. Patients should be cautioned against driving or operating machinery until it is established that they do not become somnolent.</p><p><strong>&nbsp;</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The most commonly reported adverse reactions associated with gemcitabine treatment include: nausea, with or without vomiting, and raised liver transaminases ( (AST/ ALT) and alkaline phosphatase, reported in approximately 60% of patients; proteinuria and haematuria reported in approximately 50% of patients; dyspnoea reported in 10-40% of patients (highest incidence in lung cancer patients); allergic skin rashes occurring in approximately 25% of patients, and are associated with itching in 10% of patients.</p><p>The frequency and severity of the adverse reactions are affected by the dose, infusion rate, and intervals between doses (see section 4.4). Dose-limiting adverse reactions are reductions in thrombocyte, leucocyte, and granulocyte counts (see section 4.2).</p><p>Clinical trial data</p><p>Frequencies are defined as: Very common (&ge;1/10); common (&ge;1/100 to &lt;1/10); uncommon (&ge;1/1,000 to &lt;1/100); rare (&ge;1/10,000 to &lt;1/1,000); very rare (&lt;1/10,000).</p><table border="1" cellspacing="0" cellpadding="0" style="width:662px"><tbody><tr><td style="vertical-align:top"><p><strong>System Organ Class</strong></p></td><td style="vertical-align:top"><p><strong>Frequency Grouping</strong></p></td></tr><tr><td style="vertical-align:top"><p>Blood and lymphatic system disorders</p></td><td style="vertical-align:top"><p><em>Very common: </em></p><p>&bull; Leucopenia (Neutropaenia grade 3 =19.3% ; grade 4 =6%)</p><p>&bull; Thrombocytopaenia</p><p>&bull; Anaemia</p><p>Bone marrow suppression is usually mild to moderate and mostly affects the granulocyte count (see section 4.2)</p><p><em>Common:</em></p><p>&bull; Febrile neutropenia</p><p><em>Very rare: </em></p><p>&bull; Thrombocytosis</p></td></tr><tr><td style="vertical-align:top"><p>Immune system disorders</p></td><td style="vertical-align:top"><p><em>Very rare: </em></p><p>&bull; Anaphylactoid reaction</p></td></tr><tr><td style="vertical-align:top"><p>Metabolism and nutrition disorders</p></td><td style="vertical-align:top"><p><em>Common:</em></p><p>&bull; Anorexia</p></td></tr><tr><td style="vertical-align:top"><p>Nervous system disorders</p></td><td style="vertical-align:top"><p><em>Common:</em></p><p><strong>&bull;</strong> Headache</p><p><strong>&bull;</strong> Insomnia</p><p><strong>&bull;</strong> Somnolence</p><p><strong><em>Uncommon</em> </strong></p><p>Cerebrovascular accident</p><p><em>Very rare</em></p><p>&bull; Posterior reversible encephalopathy syndrome (see section 4.4)</p></td></tr><tr><td style="vertical-align:top"><p>Cardiac disorders</p></td><td style="vertical-align:top"><p><em>Uncommon:</em></p><p>&bull; Arrhythmias, predominantly supraventricular in nature</p><p>&bull; Heart failure</p><p><em>Rare:</em></p><p>&bull; Myocardial infarct</p></td></tr><tr><td style="vertical-align:top"><p>Vascular disorders</p></td><td style="vertical-align:top"><p><em>Rare:</em></p><p>&bull; Clinical signs of peripheral vasculitis and gangrene</p><p>&bull; Hypotension</p><p><em>Very Rare</em></p><p>Capillary leak syndrome (see section 4.4)</p></td></tr><tr><td style="vertical-align:top"><p>Respiratory, thoracic and mediastinal disorders</p></td><td style="vertical-align:top"><p><em>Very common:</em></p><p>&bull; Dyspnoea -usually mild and passes rapidly without treatment</p><p><em>Common:</em></p><p>&bull; Cough</p><p>&bull; Rhinitis</p><p><em>Uncommon:</em></p><p>&bull; Interstitial pneumonitis (see section 4.4)</p><p>&bull; Bronchospasm &ndash; usually mild and transient but may require parenteral treatment</p><p><em>Rare: </em></p><p>&bull; Pulmonary oedema</p><p>&bull; Adult respiratory distress syndrome (see section 4.4)</p></td></tr><tr><td style="vertical-align:top"><p>Gastrointestinal disorders</p></td><td style="vertical-align:top"><p><em>Very common:</em></p><p>&bull; Vomiting</p><p>&bull; Nausea</p><p><em>Common:</em></p><p>&bull; Diarrhoea</p><p>&bull; Stomatitis &amp; ulceration of the mouth</p><p>&bull; Constipation</p><p><em>Very rare: </em></p><p>&bull; Ischaemic colitis</p></td></tr><tr><td style="vertical-align:top"><p>Hepatobiliary disorders</p></td><td style="vertical-align:top"><p><em>Very common:</em></p><p>&bull; Elevation of liver transaminases (AST and ALT) and alkaline phosphatase</p><p><em>Common:</em></p><p>&bull; Increased bilirubin</p><p><em>Uncommon: </em></p><p>&bull; Serious hepatotoxicity, including liver failure and death</p><p><em>Rare: </em></p><p>&bull; Increased gamma glutamyl transferase (GGT)</p></td></tr><tr><td style="vertical-align:top"><p>Skin and subcutaneous tissue disorders</p></td><td style="vertical-align:top"><p><em>Very common:</em></p><p>&bull; Allergic skin rash frequently associated with pruritus</p><p>&bull; Alopecia</p><p><em>Common:</em></p><p>&bull; Itching</p><p>&bull; Sweating</p><p><em>Rare:</em></p><p>&bull; Severe skin reactions, including desquamation and bullous skin eruptions</p><p>&bull; Ulceration</p><p>&bull; Vesicle and sore formation</p><p>&bull; Scaling</p><p><em>Very rare: </em></p><p>&bull; Toxic epidermal necrolysis</p><p>&bull; Stevens-Johnson Syndrome</p><p><em>Not known</em></p><p>&bull; Pseudocellulitis</p></td></tr><tr><td style="vertical-align:top"><p>Musculoskeletal and connective tissue disorders</p></td><td style="vertical-align:top"><p><em>Common:</em></p><p><em>&bull; </em>Back pain</p><p><em>&bull; </em>Myalgia</p></td></tr><tr><td style="vertical-align:top"><p>Renal and urinary disorders</p></td><td style="vertical-align:top"><p><em>Very common:</em></p><p>&bull; Haematuria</p><p>&bull; Mild proteinurea</p><p><em>Uncommon: </em></p><p>&bull; Renal failure (see section 4.4)</p><p>&bull; Haemolytic uraemic syndrome (see section 4.4)</p></td></tr><tr><td style="vertical-align:top"><p>General disorders and administration site conditions</p></td><td style="vertical-align:top"><p><em>Very common:</em></p><p>&bull; Influenza-like symptoms -the most common symptoms are fever, headache, chills, myalgia, asthenia, and anorexia. Cough, rhinitis, malaise, perspiration and sleeping difficulties have also been reported.</p><p>&bull; Oedema/peripheral oedema &ndash; including facial oedema. Oedema is usually reversible after stopping treatment</p><p><em>Common:</em></p><p>&bull; Fever</p><p>&bull; Asthenia</p><p>&bull; Chills</p><p><em>Rare: </em></p><p>&bull; Injection site reactions -mainly mild in nature</p></td></tr><tr><td style="vertical-align:top"><p>Injury, poisoning, and procedural complications</p></td><td style="vertical-align:top"><p><em>Rare: </em></p><p>&bull; Radiation toxicity (see section 4.5)</p><p>&bull; Radiation recall</p></td></tr></tbody></table><p><strong>Combination use in breast cancer</strong></p><p>The frequency of grade 3 and 4 haematological toxicities, particularly neutropaenia, increases when gemcitabine is used in combination with paclitaxel. However, the increase in these adverse reactions is not associated with an increased incidence of infections or haemorrhagic events. Fatigue and febrile neutropaenia occur more frequently when gemcitabine is used in combination with paclitaxel. Fatigue, which is not associated with anaemia, usually resolves after the first cycle.</p><p><strong>Grade 3 and 4 Adverse Events. Paclitaxel versus gemcitabine plus paclitaxel:</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:662px"><tbody><tr><td rowspan="3" style="vertical-align:top">&nbsp;</td><td colspan="4" style="vertical-align:top"><p><strong>Number (%) of Patients</strong></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong><u>Paclitaxel Arm</u> </strong></p><p><strong><u>(n= 259)</u> </strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Gemcitabine plus Paclitaxel Arm (n= 262)</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Grade 3</strong></p></td><td style="vertical-align:top"><p><strong>Grade 4</strong></p></td><td style="vertical-align:top"><p><strong>Grade 3</strong></p></td><td style="vertical-align:top"><p><strong>Grade 4</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Laboratory</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p><strong>Anaemia</strong></p></td><td style="vertical-align:top"><p>5(1.9)</p></td><td style="vertical-align:top"><p>1 (0.4)</p></td><td style="vertical-align:top"><p>15 (5.7)</p></td><td style="vertical-align:top"><p>3 (1.1)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Thrombocytopaenia</strong></p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>14 (5.3)</p></td><td style="vertical-align:top"><p>1 (0.4)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Neutropaenia</strong></p></td><td style="vertical-align:top"><p>11 (4.2)</p></td><td style="vertical-align:top"><p>17 (6.6)*</p></td><td style="vertical-align:top"><p>82 (31.3)</p></td><td style="vertical-align:top"><p>45 (17.2)*</p></td></tr><tr><td style="vertical-align:top"><p><strong>Non-laboratory</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p><strong>Febrile neutropenia</strong></p></td><td style="vertical-align:top"><p>3 (1.2)</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>12 (4.6)</p></td><td style="vertical-align:top"><p>1 (0.4)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Fatigue</strong></p></td><td style="vertical-align:top"><p>3 (1.2)</p></td><td style="vertical-align:top"><p>1 (0.4)</p></td><td style="vertical-align:top"><p>15 (5.7)</p></td><td style="vertical-align:top"><p>2 (0.8)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Diarrhoea</strong></p></td><td style="vertical-align:top"><p>5 (1.9)</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>8(3.1)</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td style="vertical-align:top"><p><strong>Motor neuropathy</strong></p></td><td style="vertical-align:top"><p>2 (0.8)</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>6 (2.3)</p></td><td style="vertical-align:top"><p>1 (0.4)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Sensory neuropathy</strong></p></td><td style="vertical-align:top"><p>9 (3.5)</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>14 (5.3)</p></td><td style="vertical-align:top"><p>1 (0.4)</p></td></tr></tbody></table><p>* Grade 4 neutropenia lasting for more than 7 days occurred in 12.6% of patients in the combination arm and 5.0% of patients in the paclitaxel arm.</p><p><strong>Combination use in bladder cancer </strong></p><p><strong>Grade 3 and 4 Adverse Events. MVAC versus gemcitabine plus cisplatin:</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:662px"><tbody><tr><td rowspan="3" style="vertical-align:top">&nbsp;</td><td colspan="4" style="vertical-align:top"><p><strong>Number (%) of Patients</strong></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>MVAC (methotrexate, vinblastine, doxorubicin and cisplatin) Arm</strong></p><p><strong>(n= 196)</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Gemcitabine plus cisplatin Arm (n= 200)</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Grade 3</strong></p></td><td style="vertical-align:top"><p><strong>Grade 4</strong></p></td><td style="vertical-align:top"><p><strong>Grade 3</strong></p></td><td style="vertical-align:top"><p><strong>Grade 4</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Laboratory</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p><strong>Anaemia</strong></p></td><td style="vertical-align:top"><p>30 (16)</p></td><td style="vertical-align:top"><p>4 (2)</p></td><td style="vertical-align:top"><p>47 (24)</p></td><td style="vertical-align:top"><p>7 (4)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Thrombocytopaenia</strong></p></td><td style="vertical-align:top"><p>15 (8)</p></td><td style="vertical-align:top"><p>25 (13)</p></td><td style="vertical-align:top"><p>57 (29)</p></td><td style="vertical-align:top"><p>57 (29)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Non-laboratory</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p><strong>Nausea and vomiting</strong></p></td><td style="vertical-align:top"><p>37 (19)</p></td><td style="vertical-align:top"><p>3 (2)</p></td><td style="vertical-align:top"><p>44 (22)</p></td><td style="vertical-align:top"><p>0 (0)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Diarrhoea</strong></p></td><td style="vertical-align:top"><p>15 (8)</p></td><td style="vertical-align:top"><p>1 (1)</p></td><td style="vertical-align:top"><p>6 (3)</p></td><td style="vertical-align:top"><p>0 (0)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Infection</strong></p></td><td style="vertical-align:top"><p>19 (10)</p></td><td style="vertical-align:top"><p>10 (5)</p></td><td style="vertical-align:top"><p>4 (2)</p></td><td style="vertical-align:top"><p>1 (1)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Stomatitis</strong></p></td><td style="vertical-align:top"><p>34 (18)</p></td><td style="vertical-align:top"><p>8 (4)</p></td><td style="vertical-align:top"><p>2 (1)</p></td><td style="vertical-align:top"><p>0 (0)</p></td></tr></tbody></table><p><strong>Combination use in ovarian cancer </strong></p><p><strong>Grade 3 and 4 Adverse Events. Carboplatin versus gemcitabine plus carboplatin:</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:662px"><tbody><tr><td rowspan="3" style="vertical-align:top">&nbsp;</td><td colspan="4" style="vertical-align:top"><p><strong>Number (%) of Patients</strong></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Carboplatin Arm</strong></p><p><strong>(n= 174)</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Gemcitabine plus carboplatin Arm (n= 175)</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Grade 3</strong></p></td><td style="vertical-align:top"><p><strong>Grade 4</strong></p></td><td style="vertical-align:top"><p><strong>Grade 3</strong></p></td><td style="vertical-align:top"><p><strong>Grade 4</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Laboratory</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p><strong>Anaemia</strong></p></td><td style="vertical-align:top"><p>10 (5.7)</p></td><td style="vertical-align:top"><p>4 (2.3)</p></td><td style="vertical-align:top"><p>39 (22.3)</p></td><td style="vertical-align:top"><p>9 (5.1)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Neutropaenia</strong></p></td><td style="vertical-align:top"><p>19 (10.9)</p></td><td style="vertical-align:top"><p>2 (1.1)</p></td><td style="vertical-align:top"><p>73 (41.7)</p></td><td style="vertical-align:top"><p>50 (28.6)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Thrombocytopaenia</strong></p></td><td style="vertical-align:top"><p>18 (10.3)</p></td><td style="vertical-align:top"><p>2 (1.1)</p></td><td style="vertical-align:top"><p>53 (30.3)</p></td><td style="vertical-align:top"><p>8 (4.6)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Leucopaenia</strong></p></td><td style="vertical-align:top"><p>11 (6.3)</p></td><td style="vertical-align:top"><p>1 (0.6)</p></td><td style="vertical-align:top"><p>84 (48.0)</p></td><td style="vertical-align:top"><p>9 (5.1)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Non-laboratory</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p><strong>Haemorrhage</strong></p></td><td style="vertical-align:top"><p>0 (0.0)</p></td><td style="vertical-align:top"><p>0 (0.0)</p></td><td style="vertical-align:top"><p>3 (1.8)</p></td><td style="vertical-align:top"><p>(0.0)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Febrile neutropaenia</strong></p></td><td style="vertical-align:top"><p>0 (0.0)</p></td><td style="vertical-align:top"><p>0 (0.0)</p></td><td style="vertical-align:top"><p>2 (1.1)</p></td><td style="vertical-align:top"><p>(0.0)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Infection without neutropaenia</strong></p></td><td style="vertical-align:top"><p>0 (0)</p></td><td style="vertical-align:top"><p>0 (0.0)</p></td><td style="vertical-align:top"><p>(0.0)</p></td><td style="vertical-align:top"><p>1 (0.6)</p></td></tr></tbody></table><p>Sensory neuropathy was also more frequent in the combination arm than with single agent carboplatin.</p><p><strong>To report any side effect(s): </strong></p><ul><li><strong>Saudi Arabia: </strong></li></ul><table border="1" cellspacing="0" cellpadding="0" style="width:629px"><tbody><tr><td style="vertical-align:top"><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; National Pharmacovigilance &amp; Drug Safety Centre (NPC):</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SFDA Call Center: 19999</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; E-mail: npc.drug@sfda.gov.sa</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Website: https://ade.sfda.gov.sa</p></td></tr></tbody></table><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>There is no known antidote for overdose of gemcitabine. Single doses of up to 5.7 g/m<sup>2</sup> have been administered as intravenous infusions over 30 minutes every two weeks, with clinically acceptable toxicity. In the event of suspected overdose, the patient should be monitored with appropriate blood counts and should receive supportive therapy as necessary.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: pyrimidine analogues</p><p>ATC code: L01BC05</p><p><strong>Cytotoxic Activity in Cell Culture Models:</strong></p><p>Gemcitabine exhibits significant cytotoxicity activity against a variety of cultured murine and human tumour cells. It exhibits cell phase specificity, primarily killing cells undergoing DNA synthesis (S-phase) and under certain conditions blocking the progression of cells through the G1/S-phase boundary. <em>In vitro</em> the cytotoxic action of gemcitabine is both concentration and time dependent.</p><p><strong>Antitumour Activity in Preclinical Models:</strong></p><p>In animal tumour models, the antitumour activity of gemcitabine is schedule dependent. When gemcitabine is administered daily, high animal mortality but minimal antitumoural activity is seen. If, however, gemcitabine is given every third or fourth day, it can be administered in non-lethal doses with substantial antitumoural activity against a broad spectrum of mouse tumours.</p><p><strong>Cellular Metabolism and Mechanisms of Action:</strong></p><p>Gemcitabine (dFdC), which is a pyrimidine antimetabolite, is metabolised intracellularly by nucleoside kinase to the active diphosphate (dFdCDP) and triphosphate (dFdCTP) nucleosides. The cytotoxic action of gemcitabine is due to inhibition of DNA synthesis by two actions of dFdCDP and dFdCTP. First, dFdCDP inhibits ribonucleotide reductase, which is uniquely responsible for catalysing the reactions that generate the deoxynucleoside triphosphates (dCTP) for DNA synthesis. Inhibition of this enzyme by dFdCDP causes a reduction in the concentrations of deoxynucleosides in general, and especially in that of dCTP. Second, dFdCTP competes with dCTP for incorporation into DNA (self-potentiation).</p><p>Likewise, a small amount of gemcitabine may also be incorporated into RNA. Thus, the reduction in the intracellular concentration of dCTP potentiates the incorporation of dFdCTP into DNA. DNA polymerase epsilon is essentially unable to remove gemcitabine and repair the growing DNA strands. After gemcitabine is incorporated into DNA, one additional nucleotide is added to the growing DNA strands. After this addition there is essentially a complete inhibition in further DNA synthesis (masked chain termination). After incorporation into DNA, gemcitabine then appears to induce the programmed cellular death process known as apoptosis.</p><p><strong>Clinical data:</strong></p><p><em>Bladder cancer: </em>A randomised phase III study of 405 patients with advanced or metastatic urothelial transitional cell carcinoma showed no difference between the two treatment arms, gemcitabine/cisplatin versus methotrexate/vinblastine/adriamycin/cisplatin (MVAC), in terms of median survival (12.8 and 14.8 months respectively, p=0.547), time to disease progression (7.4 and 7.6 months respectively, p=0.842) and response rate (49.4% and 45.7% respectively, p=0.512). However, the combination of gemcitabine and cisplatin had a better toxicity profile than MVAC.</p><p><em>Pancreatic cancer: </em>In a randomised phase III study of 126 patients with advanced or metastatic pancreatic cancer, gemcitabine showed a statistically significant higher clinical benefit response rate than 5-fluorouracil (23.8% and 4.8% respectively, p=0.0022). Also, a statistically significant prolongation of the time to progression from 0.9 to 2.3 months (log-rank p&lt;0.0002) and a statistically significant prolongation of median survival from 4.4 to 5.7 months (log-rank p&lt;0.0024) was observed in patients treated with gemcitabine compared to patients treated with 5-fluorouracil.</p><p><em>Non small cell lung cancer: </em>In a randomised phase III study of 522 patients with inoperable, locally advanced or metastatic NSCLC, gemcitabine in combination with cisplatin showed a statistically significant higher response rate than cisplatin alone (31.0% and 12.0%, respectively, p&lt;0.0001). A statistically significant prolongation of the time to progression, from 3.7 to 5.6 months (log-rank p&lt;0.0012) and a statistically significant prolongation of median survival from 7.6 months to 9.1 months (log-rank p&lt;0.004) was observed in patients treated with gemcitabine/cisplatin compared to patients treated with cisplatin.</p><p>In another randomised phase III study of 135 patients with stage IIIB or IV NSCLC, a combination of gemcitabine and cisplatin showed a statistically significant higher response rate than a combination of cisplatin and etoposide (40.6% and 21.2%, respectively, p=0.025). A statistically significant prolongation of the time to progression, from 4.3 to 6.9 months (p=0.014) was observed in patients treated with gemcitabine/cisplatin compared to patients treated with etoposide/cisplatin.</p><p>In both studies it was found that tolerability was similar in the two treatment arms.</p><p><em>Ovarian carcinoma: </em>In a randomised phase III study, 356 patients with advanced epithelial ovarian carcinoma who had relapsed at least 6 months after completing platinum based therapy were randomised to therapy with gemcitabine and carboplatin (GCb), or carboplatin (Cb). A statistically significant prolongation of the time to progression of disease, from 5.8 to 8.6 months (log-rank p= 0.0038) was observed in the patients treated with GCb compared to patients treated with Cb. Differences in response rate of 47.2% in the GCb arm versus 30.9% in the Cb arm (p=0.0016) and median survival 18 months (GCb) versus 17.3 (Cb) (p=0.73) favoured the GCb arm.</p><p><em>Breast cancer: </em>In a randomised phase III study of 529 patients with inoperable, locally recurrent or metastatic breast cancer with relapse after adjuvant/neoadjuvant chemotherapy, gemcitabine in combination with paclitaxel showed a statistically significant prolongation of time to documented disease progression from 3.98 to 6.14 months (log-rank p=0.0002) in patients treated with gemcitabine/paclitaxel compared to patients treated with paclitaxel. After 377 deaths, the overall survival was 18.6 months versus 15.8 months (log rank p=0.0489, HR 0.82) in patients treated with gemcitabine/paclitaxel compared to patients treated with paclitaxel and the overall response rate was 41.4% and 26.2% respectively (p= 0.0002).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The pharmacokinetics of gemcitabine have been examined in 353 patients in seven studies. The 121 women and 232 men ranged in age from 29 to 79 years. Of these patients, approximately 45% had non-small cell lung cancer and 35% were diagnosed with pancreatic cancer. The following pharmacokinetic parameters were obtained for doses ranging from 500 to 2,592 mg/m<sup>2</sup> that were infused from 0.4 to 1.2 hours.</p><p>Peak plasma concentrations (obtained within 5 minutes of the end of the infusion) were 3.2 to 45.5 &micro;g/ml. Plasma concentrations of the parent compound following a dose of 1,000 mg/m<sup>2</sup>/30-minutes are greater than 5 &mu;g/ml for approximately 30-minutes after the end of the infusion, and greater than 0.4 &mu;g/ml for an additional hour.</p><p><strong>Distribution</strong></p><p>The volume of distribution of the central compartment was 12.4 l/m<sup>2</sup> for women and 17.5 l/m<sup>2</sup> for men (inter-individual variability was 91.9%). The volume of distribution of the peripheral compartment was 47.4 l/m<sup>2</sup>. The volume of the peripheral compartment was not sensitive to gender.</p><p>The plasma protein binding was considered to be negligible.</p><p><em>Half-life:</em> This ranged from 42 to 94 minutes depending on age and gender. For the recommended dosing schedule, gemcitabine elimination should be virtually complete within 5 to 11 hours of the start of the infusion. Gemcitabine does not accumulate when administered once weekly.</p><p><strong>Metabolism:</strong></p><p>Gemcitabine is rapidly metabolised by cytidine deaminase in the liver, kidney, blood, and other tissues.</p><p>Intracellular metabolism of gemcitabine produces the gemcitabine mono, di, and triphosphates (dFdCMP, dFdCDP, and dFdCTP), of which dFdCDP and dFdCTP are considered active. These intracellular metabolites have not been detected in plasma or urine.</p><p>The primary metabolite, 2&#39;-deoxy-2&#39;,2&#39;-difluorouridine (dFdU), is not active and is found in plasma and urine.</p><p><strong>Excretion:</strong></p><p>Systemic clearance ranged from 29.2 l/hr/m<sup>2</sup> to 92.2 l/hr/m<sup>2</sup> depending on gender and age (inter-individual variability was 52.2%). Clearance for women is approximately 25% lower than the values for men. Although rapid, clearance for both men and women appears to decrease with age. For the recommended gemcitabine dose of 1,000 mg/m<sup>2</sup> given as a 30 minute infusion, lower clearance values for women and men should not necessitate a decrease in the gemcitabine dose.</p><p><em>Urinary excretion:</em> Less than 10% is excreted as unchanged drug.</p><p><em>Renal clearance was </em>2 to 7 l/hr/m<sup>2</sup>.</p><p>During the week following administration, 92 to 98% of the dose of gemcitabine administered is recovered, 99% in the urine, mainly in the form of dFdU and 1% of the dose is excreted in faeces.</p><p><strong>dFdCTP Kinetics:</strong></p><p>This metabolite can be found in peripheral blood mononuclear cells and the information below refers to these cells.</p><p>Intracellular concentrations increase in proportion to gemcitabine doses of 35-350 mg/m<sup>2</sup>/30 min, which give steady-state concentrations of 0.4-5 &micro;g/ml. At gemcitabine plasma concentrations above 5 &micro;g/ml, dFdCTP levels do not increase, suggesting that the formation is saturable in these cells.</p><p><em>Half-life of terminal elimination</em>: 0.7-12 hours.</p><p><strong>dFdU Kinetics</strong>:</p><p><em>Peak plasma concentrations (3-15 minutes after end of 30 minute infusion, 1,000 mg/m<sup>2</sup>): </em></p><p>28-52&micro;g/ml.</p><p><em>Trough concentration following once weekly dosing: </em></p><p>0.07-1.12 &micro;g/ml, with no apparent accumulation.</p><p><em>Triphasic plasma concentration versus time curve, mean half-life of terminal phase:</em></p><p>65 hours (range 33-84 hours).</p><p><em>Formation of dFdU from parent compound:</em></p><p>91%-98%.</p><p><em>Mean volume of distribution of central compartment: </em></p><p>18 l/m<sup>2</sup> (range 11-22 l/m<sup>2</sup>).</p><p><em>Mean steady-state volume of distribution (Vss):</em></p><p>150 l/m<sup>2</sup> (range 96-228 l/m<sup>2</sup>).</p><p><em>Tissue distribution:</em></p><p>Extensive.</p><p><em>Mean apparent clearance:</em></p><p>2.5 l/hr/m<sup>2</sup> (range 1-4 l/hr/m<sup>2</sup>).</p><p><em>Urinary excretion:</em></p><p>All.</p><p><em>Gemcitabine and Paclitaxel Combination Therapy:</em></p><p>Combination therapy did not alter the pharmacokinetics of either gemcitabine or paclitaxel.</p><p><em>Gemcitabine and Carboplatin Combination Therapy:</em></p><p>When given in combination with carboplatin the pharmacokinetics of gemcitabine were not altered.</p><p><strong>Renal impairment:</strong></p><p>Mild to moderate renal insufficiency (GFR from 30 ml/min to 80 ml/min) has no consistent, significant effect on gemcitabine pharmacokinetics<em>.</em></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In repeated dose studies of up to 6 months duration in mice and dogs, the principal finding was schedule and dose-dependent haematopoetic suppression, which was reversible. Gemcitabine showed mutagenic potential in an <em>in-vitro</em> mutation test and in an <em>in-vivo</em> bone marrow micronucleus test. Long-term animal studies have not been conducted to evaluate the carcinogenic potential of gemcitabine.</p><p>In fertility studies, gemcitabine caused reversible hypospermatogenesis in male mice. No effect on the fertility of females has been detected.</p><p>Evaluation of experimental animal studies has shown reproductive toxicity e.g. birth defects and other effects on the development of the embryo or foetus, the course of gestation or peri- and postnatal development.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td><p>Mannitol, E421</p><p>Sodium acetate trihydrate, E262</p><p>Hydrochloric acid (for pH-adjustment), E507</p><p>Sodium hydroxide (for pH-adjustment), E524</p><p>&nbsp;</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>This medicinal product must not be mixed with other medicinal product except those mentioned in section 6.6.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Unopened vials

2 years

After reconstitution:

Chemical and physical in-use stability has been demonstrated for 24 hours at 30°C. From a microbiological point of view, the product should be used immediately. If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and would normally not be longer than 24 hours at room temperature, unless reconstitution (and further dilution, if applicable) has taken place in controlled and validated aseptic conditions.

Solutions of reconstituted Gemcitabine should not be refrigerated, as crystallisation may occur
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em>As packaged for sale:</em></p><p>Store below 30 &deg;C</p><p><em>In-use:</em></p><p>For storage condition of the reconstituted medicinal product, see section 6.3.</p><p><strong>&nbsp;</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Gebtin</strong><strong><sup> &reg;</sup></strong><strong> Powder for Solution for Infusion</strong><strong>: &nbsp;</strong>Type I flint glass vials, with a rubber stopper and sealed with an aluminium seal, combined with a polypropylene cap.</p><p>Each pack contains 1 vial</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Reconstitution:</strong></p><p>For single use only</p><p>This medicinal product has only been shown to be compatible with sodium chloride 9 mg/ml (0.9%) solution for injection. Accordingly, only this diluent should be used for reconstitution. Compatibility with other active substances has not been studied. Therefore, it is not recommended to mix this medicinal product with other active substances when reconstituted.</p><p>Reconstitution at concentrations greater than 38 mg/ml may result in incomplete dissolution, and should be avoided.</p><p>To reconstitute, slowly add the appropriate volume of sodium chloride 9 mg/ml (0.9%) solution for injection (as stated in the table below) and shake to dissolve.</p><table border="1" cellspacing="0" cellpadding="0" style="width:651px"><tbody><tr><td style="vertical-align:top"><p>Presentation</p></td><td style="vertical-align:top"><p>Volume of sodium chloride 9 mg/ml (0.9%) solution for injection to be added</p></td><td style="vertical-align:top"><p>Displacement volume</p></td><td style="vertical-align:top"><p>Final concentration</p></td></tr><tr><td style="vertical-align:top"><p>200 mg</p></td><td style="vertical-align:top"><p>5 ml</p></td><td style="vertical-align:top"><p>0.26 ml</p></td><td style="vertical-align:top"><p>38 mg/ml</p></td></tr><tr><td style="vertical-align:top"><p>1 g</p></td><td style="vertical-align:top"><p>25 ml</p></td><td style="vertical-align:top"><p>1.3 ml</p></td><td style="vertical-align:top"><p>38 mg/ml</p></td></tr><tr><td style="vertical-align:top"><p>2 g</p></td><td style="vertical-align:top"><p>50 ml</p></td><td style="vertical-align:top"><p>2.6 ml</p></td><td style="vertical-align:top"><p>38 mg/ml</p></td></tr></tbody></table><p>The appropriate amount of medicinal product may be further diluted with sodium chloride 9 mg/ml (0.9%) solution for injection.</p><p>Parenteral medicinal products should be inspected visually for particulate matter and discolouration, prior to administration, whenever solution and container permit.</p><p>Any unused solution should be discarded as described below.</p><p><strong>Guidelines for the Safe Handling of Cytotoxic Medicinal Products:</strong></p><p>Local guidelines on safe preparation and handling of cytotoxic medicinal products must be adhered to. Cytotoxic preparations should not be handled by pregnant staff. The preparation of injectable solutions of cytotoxic agents must be carried out by trained specialist personnel with knowledge of the medicines used. This should be performed in a designated area. The work surface should be covered with disposable plastic-backed absorbent paper.</p><p>Suitable eye protection, disposable gloves, face mask and disposable apron should be worn. Precautions should be taken to avoid the medicinal product accidentally coming into contact with the eyes. If accidental contamination occurs, the eye should be washed with water thoroughly and immediately.</p><p>Syringes and infusion sets should be assembled carefully to avoid leakage (use of Luer lock fittings is recommended). Large bore needles are recommended to minimise pressure and the possible formation of aerosols. The latter may also be reduced by the use of a venting needle.</p><p>Actual spillage or leakage should be mopped up wearing protective gloves. Excreta and vomit must be handled with care.</p><p><strong>Disposal:</strong></p><p>Adequate care and precaution should be taken in the disposal of items used to reconstitute this medicinal product. Any unused dry product or contaminated materials should be placed in a high-risk waste bag. Sharp objects (needles, syringes, vials, etc) should be placed in a suitable rigid container. Personnel concerned with the collection and disposal of this waste should be aware of the hazard involved. Waste material should be destroyed by incineration. Any unused product or waste material should be disposed of in accordance with local requirements.</p><p><strong>Handling:</strong></p><p><strong>&nbsp;</strong></p><p>The normal safety precautions for cytostatic agents must be observed when preparing and disposing of the infusion solution. Handling of the solution for infusion should be done in a safety box and protective coats and gloves should be used. If no safety box is available, the equipment should be supplemented with a mask and protective glasses.</p><p>If the preparation comes into contact with the eyes, this may cause serious irritation. The eyes should be rinsed immediately and thoroughly with water. If there is lasting irritation, a doctor should be consulted. If the solution is spilled on the skin, rinse thoroughly with water.</p><p>Instructions for reconstitution (and further dilution, if performed)</p><p>The only approved diluent for reconstitution of Gemcitabine sterile powder is sodium chloride 9 mg/ml (0.9%) solution for injection (without preservative). Due to solubility considerations, the maximum concentration for Gemcitabine upon reconstitution is 40 mg/ml. Reconstitution at concentrations greater than 40 mg/ml may result in incomplete dissolution and should be avoided.</p><p>1. Use aseptic technique during the reconstitution and any further dilution of Gemcitabine for intravenous infusion administration.</p><p>2. To reconstitute, add 5 ml of sterile sodium chloride 9 mg/ml (0.9 %) solution for injection, without preservative, to the 200 mg vial or 25 ml sterile sodium chloride 9 mg/ml (0.9 %) solution for injection, without preservative, to the 1,000 mg vial. The total volume after reconstitution is 5.26 ml (200 mg vial) or 26.3 ml (1,000 mg vial) respectively. This yields a Gemcitabine concentration of 38 mg/ml, which includes accounting for the displacement volume of the lyophilized powder. Shake to dissolve. Further dilution with sterile sodium chloride 9 mg/ml (0.9 %) solution for injection, without preservative, can be done. Reconstituted solution is a clear, colorless to light straw-coloured solution.</p><p>3. Parenteral medicinal products should be inspected visually for particulate matter and discolouration prior to administration. If particulate matter is observed, do not administer.</p><p>Any unused product or waste material should be disposed of in accordance with local requirements.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                MS Pharma Saudi
Riyadh, Kingdome Saudi Arabia. 
medical-ksa@mspharma.com

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                May,2021
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>